- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03731182
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
21. mai 2021 oppdatert av: Merck Sharp & Dohme LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (PNEU-SICKLE)
This study is designed to describe the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
104
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Salvador, Brasil, 40420-000
- Hospital Santo Antonio - Obras Sociais Irma Dulce ( Site 0205)
-
Sao Paulo, Brasil, 01221-900
- Santa Casa de Misericordia de Sao Paulo ( Site 0202)
-
-
MG
-
Belo Horizonte, MG, Brasil, 30150-221
- Santa Casa de Misericordia de Belo Horizonte ( Site 0200)
-
-
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia, 080020
- Clinica de la Costa Ltda. ( Site 0300)
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, Colombia, 760045
- Centro de Estudios en Infectologia Pediatrica SAS ( Site 0301)
-
-
-
-
-
Santo Domingo, Den dominikanske republikk, 10122
- Clinical Research Republica Dominicana ( Site 0401)
-
Santo Domingo, Den dominikanske republikk, 10205
- Caimed Dominicana S.A.S ( Site 0400)
-
-
Santo Domingo
-
Distrito Nacional, Santo Domingo, Den dominikanske republikk, 10204
- Fundacion Dominicana de Perinatologia PRO BEBE INC ( Site 0402)
-
-
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Nemours/Alfred I. duPont Hospital for Children ( Site 0113)
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30303
- Children's Healthcare of Atlanta ( Site 0100)
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Children's Hospital of Michigan ( Site 0111)
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07112
- Newark Beth Israel Medical Center ( Site 0115)
-
-
New York
-
Rochester, New York, Forente stater, 14642
- University of Rochester Medical Center ( Site 0105)
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital Medical Center ( Site 0101)
-
-
-
-
-
Athens, Hellas, 115 27
- Agia Sophia Children s Hospital ( Site 0700)
-
Thessaloniki, Hellas, 546 42
- Hippokration General Hospital of Thessaloniki ( Site 0701)
-
-
-
-
-
Genova, Italia, 16132
- Ospedale San Martino ( Site 0800)
-
-
-
-
-
Panama, Panama, 0816-00383
- Cevaxin ( Site 0500)
-
Panama, Panama, 0816-00383
- Cevaxin ( Site 0502)
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
5 år til 17 år (Barn)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Documented diagnosis of sickle cell disease in their medical record
Female participants: not pregnant or breastfeeding, and at least 1 of the following conditions apply:
1) not a woman of childbearing potential (WOCBP) as defined in the protocol, or 2) a WOCBP who agrees to follow the contraceptive guidance in the protocol during the treatment period and for at least 6 weeks after the last dose of study vaccine
- Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent/assent.
Exclusion Criteria:
- History of Invasive Pneumococcal Disease (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)
- Known hypersensitivity to any component of pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine
- Known or suspected impairment of immunological function
- History of congenital or acquired immunodeficiency
- Documented human immunodeficiency virus (HIV) infection
- History of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, or type 1 diabetes mellitus)
- Known coagulation disorder contraindicating intramuscular vaccination
- History of malignancy ≤5 years prior to signing informed consent/assent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- A WOCBP who has a positive urine or serum pregnancy test before the first vaccination at Visit 1 (Day 1)
- Received any PCV or pneumococcal polysaccharide vaccine <3 years before Visit 1 (Day 1)
- Five (5) years of age and has received <3 doses of PCV
- Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease. Note: hydroxyurea is permitted
- Received immunoglobulin within 6 months before receipt of study vaccine
- Participated in another clinical study of an investigational product within 2 months before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included
- Recent history (within the last year) of more than 3 inpatient hospitalizations
- At the time of signing informed consent/assent, is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence as assessed by the study investigator
- History or current evidence of any condition, therapy, lab abnormality or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study in the opinion of the Investigator
- Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: V114
Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
|
V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
|
|
Aktiv komparator: Prevnar 13™
Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
|
Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With a Solicited Injection-site Adverse Event
Tidsramme: Up to 14 days post-vaccination
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Solicited injection-site AEs included injection-site erythema (redness), injection-site induration (hard lump), injection-site pain (tenderness), and injection-site swelling.
|
Up to 14 days post-vaccination
|
|
Percentage of Participants With a Solicited Systemic Adverse Event
Tidsramme: Up to 14 days post-vaccination
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Solicited systemic AEs included arthralgia (joint pain), fatigue (tiredness), headache, myalgia (muscle pain), and urticaria (hives or welts).
|
Up to 14 days post-vaccination
|
|
Percentage of Participants With a Vaccine-related Serious Adverse Event
Tidsramme: Up to 6 months post-vaccination
|
A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.
SAEs that were reported by the investigator to be at least possibly related to the study vaccination were summarized.
|
Up to 6 months post-vaccination
|
|
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at Day 30
Tidsramme: Day 30
|
The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.
|
Day 30
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) at Day 30
Tidsramme: Day 30
|
Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 using the multiplexed opsonophagocytic assay (MOPA).
|
Day 30
|
|
Geometric Mean Fold Rise (GMFR) in Serotype-specific IgG From Day 1 (Baseline) to Day 30
Tidsramme: Day 1 (Baseline) and Day 30
|
IgG for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes unique to V114 (22F and 33F) was determined using an electrochemiluminescence assay.
GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline (Day 1, pre-vaccination).
|
Day 1 (Baseline) and Day 30
|
|
GMFR in Serotype-specific OPA From Day 1 (Baseline) to Day 30
Tidsramme: Day 1 (Baseline) and Day 30
|
Activity for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes unique to V114 (22F and 33F) was determined using a MOPA.
GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline (Day 1, pre-vaccination).
|
Day 1 (Baseline) and Day 30
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
23. januar 2019
Primær fullføring (Faktiske)
8. juni 2020
Studiet fullført (Faktiske)
8. juni 2020
Datoer for studieregistrering
Først innsendt
2. november 2018
Først innsendt som oppfylte QC-kriteriene
2. november 2018
Først lagt ut (Faktiske)
6. november 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. juni 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
21. mai 2021
Sist bekreftet
1. mai 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Infeksjoner
- Hematologiske sykdommer
- Genetiske sykdommer, medfødte
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Streptokokkinfeksjoner
- Gram-positive bakterielle infeksjoner
- Anemi
- Anemi, hemolytisk, medfødt
- Anemi, hemolytisk
- Hemoglobinopatier
- Pneumokokkinfeksjoner
- Anemi, sigdcelle
- Fysiologiske effekter av legemidler
- Immunologiske faktorer
- Heptavalent pneumokokkkonjugatvaksine
Andre studie-ID-numre
- V114-023 (Annen identifikator: Merck Protocol Number)
- 2018-001152-35 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ja
IPD-planbeskrivelse
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .